OSA LAAA MERGER CORP

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society

PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at , a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, June 1-5 in Houston, TX.

  • Abstract ID 1262

    “Evaluating the Clinical Performance of a Novel, Precision Oral Appliance Therapy Medical Device Made Wholly from a Medical Grade Class VI Material for the Treatment of Obstructive Sleep Apnea”



    E Sall1; K Smith2; A Desai3; JA Carollo4; MT Murphy5; S Kim6; LA Liptak6

    1GoTo Sleep Center, Glendale, AZ

    2Star Sleep & Wellness, Frisco, TX

    3London Bridge Hospital, London, GBR

    4Dental Sleep Medicine of New Jersey, Florham Park, NJ

    5Funktional Sleep, Rochester Hills, MI

    6ProSomnus Sleep Technologies, Pleasanton, CA

This study evaluated the clinical performance of a novel, precision oral appliance therapy (ProSomnus OAT) medical device made entirely from a US Pharmacopeia (USP) medical grade class VI qualified material for the treatment of OSA. Data from 91 patients with OSA found that 98% of patients with mild and moderate OSA were successfully treated to an AHI < 10 events per hour. No patients discontinued treatment due to material-related side effects. The results of the study show that a precision ProSomnus OAT device made from USP Class VI qualified material is safe and efficacious for the treatment of OSA.

  • Abstract ID 0606

    “Post Market Surveillance from Precision OAT Cases Indicates High Levels of Patient and Provider Satisfaction”



    Len Liptak, MBA1, Yoann Ojeda, MDT1, Mark Murphy DDS2

    1ProSomnus Sleep Technologies, Pleasanton, CA

    2Funktional Sleep, Rochester Hills, MI

Review of post-market surveillance surveys collected from 10,880 patients and 646 providers over a 60-month period showed that 98% of patients and providers reported a ‘first time fit’, indicating a high-quality device made precisely to specification. 99% of patients reported being satisfied with their appliance and 98% of providers reported being satisfied with the device upon delivery to the patient. These results indicate that ProSomnus precision OAT devices are associated with high levels of satisfaction among patients and providers.

“A growing number of physicians are realizing the need for non-CPAP OSA therapy, due to recent research documenting patient preferences, FDA recalls, treatment compliance and treatment effectiveness rates,” noted Len Liptak, Chief Executive Officer. “ProSomnus is proud to be associated with these scientific abstracts which further investigate and establish the clinical safety and performance of precision oral appliance therapy for patients with Obstructive Sleep Apnea.”

About ProSomnus

ProSomnus is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit .

Investor Contact

Mike Cavanaugh

ICR Westwicke

Phone: +1.617.877.9641

Email:

Media Contact

Heather Whalen

ProSomnus

Phone: +1.925.360.2990

Email:



EN
30/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LAAA MERGER CORP

 PRESS RELEASE

ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges ...

ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization PLEASANTON, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced record revenues for the quarter ended June 30, 2024 as it formally emerges from reorganization on August 5, 2024. Revenues for the second quarter totaled a record $9.1 million reflecting increasing orders for the Company’s precision intraoral medical devices. These quarterly results reflect a 22% increase over the first quarter of ...

 PRESS RELEASE

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLE...

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at , a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, June 1-5 in Houston, TX. Abstract ID 1262“Evaluating the Clinical Performance of a N...

 PRESS RELEASE

ProSomnus Announces Strong First Quarter 2024 Revenue Growth

ProSomnus Announces Strong First Quarter 2024 Revenue Growth ProSomnus Records 28% Year-Over-Year Revenue Growth Accompanied by Continued Strong Customer Satisfaction PLEASANTON, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, today announced results for the first quarter ended March 31, 2024. Revenue for the first quarter of 2024 totaled $7.5 million, an increase of $1.7 million or 28% compared to $5.8 million for the first quarter of 2023 representing one of the highest growth rates in sleep medicin...

 PRESS RELEASE

ProSomnus Contributes Two Scientific Abstracts Accepted for Presentati...

ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting PLEASANTON, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at the 2024 American Academy of Dental Sleep Medicine Meeting in New Orleans. Abstract #019“Assessing Health Outcomes When Treating Obstructive Sleep Apnea with Mandibular Protruding Appliances”Erin ...

 PRESS RELEASE

Four Independent Scientific Abstracts at the American Academy of Denta...

Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices PLEASANTON, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that four independent scientific abstracts accepted for the 2024 AADSM Annual Meeting contain scientific data utilizing ProSomnus precision devices, with one abstract winning the prestigious Clinical Excellence Award, and another featuring over 1,200 patients. Abstract #018 (Winner of t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch